239 related articles for article (PubMed ID: 1806446)
1. Idarubicin in blastic crisis of chronic myelogenous leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
[TBL] [Abstract][Full Text] [Related]
3. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
8. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
10. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
11. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
14. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
16. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
Creutzig U; Körholz D; Niemeyer CM; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Klin Padiatr; 2000; 212(4):163-8. PubMed ID: 10994544
[TBL] [Abstract][Full Text] [Related]
17. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
18. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Robak T; Góra-Tybor J
Neoplasma; 2001; 48(3):203-7. PubMed ID: 11583290
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
